A study from the Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; and PRESTO, Japan Science and Technology Agency, Saitama, Japan has reported that “Inhibition of Endothelial p53 Improves Metabolic Abnormalities..”
This study was published in the June 12, 2014 Cell Reports by Prof. Minamino T, Yokoyama and others from the Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; and PRESTO, Japan Science and Technology Agency, Saitama, Japan.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNAs-based therapy for Cardiovascular and metabolic disorders: MiRNA-375 improves cardiovascular and metabolic abnormalities via down regulation of its target gene. This study suggests that miR-375, by down regulating its target gene, it may improve cardiovascular and metabolic abnormalities. Together, this study suggests that pharmacological formulations containing “miR-375 or its small molecule activators” can be used to treat cardiovascular and metabolic abnormalities.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at info@genomediscovery.org
Citation: Boominathan, MiRNAs-based therapy for Cardiovascular and metabolic disorders: MiRNA-375 improves cardiovascular and metabolic abnormalities via down regulation of its target gene, 6/July/2014, 4.59 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
*Research cooperation
